Bangladesh is rolling out covid-19 vaccine from almost all sources. Due to the variation people are in dilemma about which vaccine they should pick and which one is better than others. Here are some comparison our pharma correspondent Soumen Mostafiz has compiled on for our readers.

Oxford-AstraZeneca
How does it work?
Scientists have taken genes from the spike protein on COVID-19 and inserted them into a harmless common cold virus to create their vaccine. When injected into the body, cells begin to reproduce the spike protein. This immune system retaliates by producing antibodies and creating T-Cells to destroy those cells and prevent the person from falling ill. Two doses of the vaccine are meant to be 62 percent effective.
How effective is it?
Results from trials using two doses of the vaccine taken up to three months apart found it to be 62 percent effective – that’s higher than the seasonal flu vaccine which is roughly 50 percent effective. Scientists are now waiting to see if the vaccine stops transmission of the virus.
Sinovac and Sinopharm

China’s Sinovac and Sinopharm vaccines use the same approach as the Oxford vaccine to provide immunity from COVID-19. Killed viral particles from the virus are injected into the body, which triggers an immune response and stops a person from falling seriously ill when they contract COVID-19.
How effective is it?
On Wednesday, Sinopharm said results from trials showed its vaccine to be 79 percent effective and it has already been approved in the United Arab Emirates. Researchers in Brazil say the Sinovac vaccine is more than 50 percent effective.
Sputnik-V
How does it work?
The Sputnik-V vaccine uses an inactivated virus, just like the Oxford, Sinovac and Sinopharm vaccines to stimulate an immune response from the body.
How effective is it?
Trials showed the vaccine proved to be more than 90 percent effective in individuals aged over 60 years, according to the makers. Further tests are ongoing to see if it has the same impact on different age groups.

Chinese vaccine will be available more faster and easier in the next couple of weeks meant people will feel confused about the vaccine.
One Chinese study published in scientific journal The Lancet, only has information from the first and second phase trials of CoronaVac in China.
Zhu Fengcai, one of the paper’s authors, said those results – based on 144 participants in the phase one trial and 600 in the phase two trial – meant the vaccine was “suitable for emergency use”.
CoronaVac has been undergoing phase three trials in various countries. Interim data from late-stage trials in Turkey and Indonesia showed that the vaccine was 91.25% and 65.3% effective respectively.
Researchers in Brazil initially said it was 78% effective in their clinical trials, but in January 2021 revised that figure to 50.4% after including more data in their calculations. Earlier in November, their trials were briefly halted after the reported death of a volunteer, but resumed after the death was found to have no links to the vaccine.